Focused On-demand Library for Coiled-coil domain-containing protein 40

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Our library distinguishes itself through several key aspects:

  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.







Alternative names:


Alternative UPACC:

Q4G0X9; A8MTD2; C9JTI9; C9JTJ0; C9JXW1; J3QSY2; Q6PE47; Q9HCD2; Q9NWL5


Coiled-coil domain-containing protein 40 plays a pivotal role in ciliary and flagellar motility, essential for respiratory health and male fertility. It is crucial for the assembly of dynein regulatory complex (DRC) and inner dynein arm (IDA) complexes, ensuring the precise regulation of ciliary beat. This protein, in collaboration with CCDC39, establishes the structural integrity of cilia and flagella, facilitating their functional efficacy.

Therapeutic significance:

Given its central role in primary ciliary dyskinesia, particularly in forms with inner dynein arm defects and axonemal disorganization, Coiled-coil domain-containing protein 40 is a significant target for therapeutic intervention. Understanding its function and the genetic variants affecting it could lead to novel treatments for this debilitating condition, offering hope for improved respiratory health and fertility outcomes.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.